自己免疫性精神病市場 - 市場の洞察、疫学、市場予測：2034年

2023年には主要7ヶ国で約561件の自己免疫性精神病の有病例が診断されました。このうち、米国が症例の38.9%を占め、EU4ヶ国と英国がそれぞれ約39.5%、日本が21.5%を占めました。

自己免疫性精神病の市場規模は、2024年から2034年にかけて高いCAGRが予測されており、着実な成長が見込まれています。主要7ヶ国にわたるこの成長は、サトラリズマブ（RG-6168）やART5803などの革新的な治療法の導入により推進されます。さらに、自己免疫疾患や薬物乱用などの認識とリスク要因の増加によって、自己免疫性精神病の有病率が上昇し、市場の拡大に貢献するとみられています。

主要7ヶ国の自己免疫性精神病の市場規模は、2023年に約607万米ドルとなりました。同市場は、2024年から2034年の予測期間中、18.6%のCAGRで拡大すると予測されています。

自己免疫性精神病の治療情勢は未だ未開発であり、FDA承認の治療法はなく、現在の治療法では症状の緩和は限定的で、副作用も大きいです。治療結果を改善し、再発を減らすための標的療法が極めて必要とされています。

当レポートでは、主要7ヶ国における自己免疫性精神病市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 重要な出来事

第6章 疾患の背景と概要

• イントロダクション
• 分類
• 原因とリスク要因
• 兆候と症状
• 診断
• 治療と管理

第7章 調査手法

第8章 疫学と患者人口

• 主な調査結果
• 仮定と根拠
• 主要7ヶ国における自己免疫性精神病の診断済み有病者総数
• 主要7ヶ国における自己免疫性精神病の診断済み有病症例総数
• 米国
• EU4ヶ国と英国
• 日本

第9章 患者動向

第10章 新興薬剤

第11章 自己免疫性精神病-主要7ヶ国市場分析

• 主な調査結果
• 市場見通し
• 主要な市場予測の前提条件
• 主要7ヶ国における自己免疫性精神病の総市場規模
• 主要7ヶ国における自己免疫性精神病の市場規模、治療法別
• 米国の市場規模
• EU4ヶ国と英国の市場規模
• 日本市場規模

第12章 KOLの見解

第13章 アンメットニーズ

第14章 SWOT

第15章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

List of Tables

• Table 1: Summary of Epidemiology and Market (2020-2034)
• Table 2: Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in the 7MM (2020-2034)
• Table 3: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in the 7MM (2020-2034)
• Table 4: Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in the US (2020-2034)
• Table 5: Total Cases of Autoimmune Encephalitis with Neuronal Surface Antigens in the US (2020-2034)
• Table 6: Antibodies-specific Cases of Autoimmune Encephalitis in the US (2020-2034)
• Table 7: Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in the US (2020-2034)
• Table 8: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in the US (2020-2034)
• Table 9: Relapsed Cases of Autoimmune Psychosis in the US (2020-2034)
• Table 10: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in EU4 and the UK (2020-2034)
• Table 11: Total Cases of Autoimmune Encephalitis With Neuronal Surface Antigens in EU4 and the UK (2020-2034)
• Table 12: Antibodies-specific Cases of Autoimmune Encephalitis in EU4 and the UK (2020-2034)
• Table 13: Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in EU4 and the UK (2020-2034)
• Table 14: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in EU4 and the UK (2020-2034)
• Table 15: Relapsed Cases of Autoimmune Psychosis in EU4 and the UK (2020-2034)
• Table 16: Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in Japan (2020-2034)
• Table 17: Total Cases of Autoimmune Encephalitis With Neuronal Surface Antigens in Japan (2020-2034)
• Table 18: Antibodies-specific Cases of Autoimmune Encephalitis in Japan (2020-2034)
• Table 19: Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in Japan (2020-2034)
• Table 20: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in Japan (2020-2034)
• Table 21: Relapsed Cases of Autoimmune Psychosis in Japan (2020-2034)
• Table 22: Comparison of Emerging Drugs Under Development for Autoimmune Psychosis
• Table 23: ENSPRYNG (satralizumab, RG6168), Clinical Trial Description, 2024
• Table 24: ART5803, Clinical Trial Description, 2024
• Table 25: Key Market Forecast Assumption of Autoimmune Psychosis in the US
• Table 26: Key Market Forecast Assumption of Autoimmune Psychosis in EU4 and the UK
• Table 27: Key Market Forecast Assumption of Autoimmune Psychosis in Japan
• Table 28: Total Market Size of Autoimmune Psychosis in the 7MM, in USD thousands (2020-2034)
• Table 29: Market Size of Autoimmune Psychosis by Therapies in the 7MM, in USD thousands (2020-2034)
• Table 30: Total Market Size of Autoimmune Psychosis in the US, in USD thousands (2020-2034)
• Table 31: Market Size of Autoimmune Psychosis by Therapies in the US, in USD thousands (2020-2034)
• Table 32: Total Market Size of Autoimmune Psychosis in EU4 and the UK, in USD thousands (2020-2034)
• Table 33: Market Size of Autoimmune Psychosis by Therapies in EU4 and the UK, in USD thousands (2020-2034)
• Table 34: Total Market Size of Autoimmune Psychosis in Japan, in USD thousands (2020-2034)
• Table 35: Market Size of Autoimmune Psychosis by Therapies in Japan, in USD thousands (2020-2034)

List of Figures

• Figure 1: Classification of Autoimmune Psychosis
• Figure 2: Symptoms of Autoimmune Psychosis
• Figure 3: Diagnostic Elements Possibly Supporting the Definition of Autoimmune Psychosis
• Figure 4: Algorithm for the Diagnosis of Autoimmune Encephalitis
• Figure 5: Therapeutic Algorithm for Autoimmune Encephalitis
• Figure 6: Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in the 7MM (2020-2034)
• Figure 7: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in the 7MM (2020-2034)
• Figure 8: Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in the US (2020-2034)
• Figure 9: Total Cases of Autoimmune Encephalitis with Neuronal Surface Antigens in the US (2020-2034)
• Figure 10: Antibodies-specific Cases of Autoimmune Encephalitis in the US (2020-2034)
• Figure 11: Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in the US (2020-2034)
• Figure 12: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in the US (2020-2034)
• Figure 13: Relapsed Cases of Autoimmune Psychosis in the US (2020-2034)
• Figure 14: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in EU4 and the UK (2020-2034)
• Figure 15: Total Cases of Autoimmune Encephalitis With Neuronal Surface Antigens in EU4 and the UK (2020-2034)
• Figure 16: Antibodies-specific Cases of Autoimmune Encephalitis in EU4 and the UK (2020-2034)
• Figure 17: Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in EU4 and the UK (2020-2034)
• Figure 18: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in EU4 and the UK (2020-2034)
• Figure 19: Relapsed Cases of Autoimmune Psychosis in EU4 and the UK (2020-2034)
• Figure 20: Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in Japan (2020-2034)
• Figure 21: Total Cases of Autoimmune Encephalitis With Neuronal Surface Antigens in Japan (2020-2034)
• Figure 22: Antibodies-specific Cases of Autoimmune Encephalitis in Japan (2020-2034)
• Figure 23: Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in Japan (2020-2034)
• Figure 24: Total Diagnosed Prevalent Cases of Autoimmune Psychosis in Japan (2020-2034)
• Figure 25: Relapsed Cases of Autoimmune Psychosis in Japan (2020-2034)
• Figure 26: Total Market Size of Autoimmune Psychosis in the 7MM, in USD thousands (2020-2034)
• Figure 27: Total Market Size of Autoimmune Psychosis by Therapies in the 7MM, in USD thousands (2020-2034)
• Figure 28: Total Market Size of Autoimmune Psychosis in the US, in USD thousands (2020-2034)
• Figure 29: Market Size of Autoimmune Psychosis by Therapies in the US, in USD thousands (2020-2034)
• Figure 30: Total Market Size of Autoimmune Psychosis in EU4 and the UK, in USD thousands (2020-2034)
• Figure 31: Market Size of Autoimmune Psychosis by Therapies in EU4 and the UK, in USD thousands (2020-2034)
• Figure 32: Total Market Size of Autoimmune Psychosis in Japan, in USD thousands (2020-2034)
• Figure 33: Market Size of Autoimmune Psychosis by Therapies in Japan, in USD thousands (2020-2034)
• Figure 34: Unmet Needs
• Figure 35: SWOT Analysis
• Figure 36: Health Technology Assessment
• Figure 37: Reimbursement Process in Germany
• Figure 38: Reimbursement Process in France
• Figure 39: Reimbursement Process in Italy
• Figure 40: Reimbursement Process in Spain
• Figure 41: Reimbursement Process in the United Kingdom
• Figure 42: Reimbursement Process in Japan

Key Highlights:

• According to DelveInsight's estimates, in 2023, there were approximately 561 diagnosed prevalent cases of autoimmune psychosis in the 7MM. Of these, the United States accounted for 38.9% of the cases, while EU4 and the UK accounted for nearly 39.5% and Japan represented 21.5% of the cases, respectively.
• The autoimmune psychosis market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) forecasted from 2024 to 2034. This growth across the 7MM will be propelled by the introduction of innovative therapies such as satralizumab (RG-6168) and ART5803. Furthermore, the rising prevalence of autoimmune psychosis, driven by increasing awareness and risk factors like autoimmune diseases and substance abuse, will contribute to the market's expansion.
• According to DelveInsight's analysis, the autoimmune psychosis market in the 7MM was valued at approximately USD 6.07 million in 2023. Over the forecast period from 2024 to 2034, this market is projected to grow at a CAGR of 18.6%.
• The treatment landscape for autoimmune psychosis remains underdeveloped, with no FDA-approved treatments, with current therapies offering limited symptom relief and significant side effects. There is a critical need for targeted therapies to improve outcomes and reduce relapses.
• Hoffmann-La Roche, and Arialys Therapeutics are advancing their assets through various stages of development, driving innovation in the autoimmune psychosis market. Their efforts are shaping a dynamic landscape and opening up significant opportunities for market growth and expansion.
• Roche's ENSPRYNG (satralizumab), a pioneering emerging therapy, is currently in Phase III of clinical development. Hoffmann-La Roche plans to submit a regulatory filing by 2026 for its potential use in treating autoimmune encephalitis.

DelveInsight's "Autoimmune Psychosis - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of autoimmune psychosis, historical and forecasted epidemiology, as well as the autoimmune psychosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The autoimmune psychosis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM autoimmune psychosis market size from 2020 to 2034. The report also covers autoimmune psychosis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Autoimmune Psychosis Understanding and Treatment Algorithm

Autoimmune psychosis overview

Autoimmune psychosis is characterized by isolated psychotic symptoms with minimal or no neurological signs in patients who test positive for antibodies targeting neuronal membrane receptors, such as N-methyl-D-aspartate receptors (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), and gamma-aminobutyric acid type A receptor (GABA-A). Particularly, antibodies against NMDAR disrupt neurotransmission, leading to psychosis and encephalitis-related symptoms. While these cases are often categorized as atypical or mild forms of autoimmune encephalitis, some experts suggest their distinct nature warrants recognition as a separate condition, autoimmune psychosis. It is classified into possible, probable, or definitive forms.

Key risk factors for autoimmune psychosis include immune dysregulation, genetic predisposition, and coexisting autoimmune conditions like lupus and multiple sclerosis. These factors highlight the importance of antibody screening in cases of treatment-resistant psychosis.

Symptoms of autoimmune psychosis include hallucinations, delusions, agitation, aggression, slow thinking, and anxiety, among others.

Autoimmune psychosis diagnosis

Autoimmune psychosis can be diagnosed using MRI, electroencephalogram, blood serological tests, and lumbar puncture. However, some critics argue that this approach may miss patients without neurological signs and have suggested alternative diagnostic criteria. Cerebrospinal fluid (CSF) analysis is essential for diagnosing autoimmune encephalitis and is typically conducted after a brain MRI. A lumbar puncture is required for suspected cases unless contraindicated.

Autoimmune psychosis treatment

Currently, there are no approved therapies for treating autoimmune psychosis. Although considered a milder form of autoimmune encephalitis, it requires the same prompt treatment as other forms of the condition. Treatment usually focuses on removing tumors and antibodies while temporarily suppressing the body's ability to produce more. Common approaches include corticosteroids, IVIg, plasmapheresis, rituximab, anticonvulsants, and psychiatric medications.

Autoimmune Psychosis Epidemiology

As the market is derived using a patient-based model, the autoimmune psychosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of autoimmune encephalitis, total cases of autoimmune encephalitis with neuronal surface antigens, antibodies-specific cases of autoimmune encephalitis, gender-specific cases of anti-NMDAR autoimmune encephalitis, total diagnosed prevalent cases of autoimmune psychosis and relapsed cases of autoimmune psychosis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• In 2023, there were an estimated 84,441 diagnosed prevalent cases of autoimmune encephalitis across the 7MM, with the number expected to rise by 2034.
• In 2023, the US recorded approximately 30,123 cases of autoimmune encephalitis with neuronal surface antigens, a figure projected to grow by 2034.
• In 2023, the US reported the following cases of antibody-specific autoimmune encephalitis: 4,362 cases for anti-NMDAR, 10,359 for anti-LGI1, 1,227 for anti-CASPR2, 409 for anti-GABAbR, 3,135 for anti-GAD, and 10,632 for other antibodies (including GFAP, ANNA-2, unclassified Ab, CRMP5, etc.).
• In 2023, there were approximately 799 male and 3,635 female cases of anti-NMDAR encephalitis across the EU4 and the UK.
• According to DelveInsight's estimates, there were approximately 561 diagnosed prevalent cases of autoimmune psychosis across the 7MM in 2023, with the number expected to rise by 2034.
• In 2023, the US accounted for approximately 218 diagnosed prevalent cases of autoimmune psychosis, while the EU4 and the UK reported nearly 222 cases, and Japan recorded approximately 121 cases.
• In 2023, Japan reported nearly 38 relapse cases of autoimmune psychosis, a number expected to rise by 2034.

Autoimmune Psychosis Drug Chapters

The drug chapter segment of the autoimmune psychosis report encloses a detailed analysis of autoimmune psychosis-marketed drugs and mid to late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the autoimmune psychosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

ENSPRYNG (satralizumab, RG6168): Hoffmann-La Roche (Chugai Pharmaceutical)

ENSPRYNG (satralizumab), developed by Chugai using innovative antibody recycling technology, is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor. It has been approved in over 60 countries for use in adults and adolescents with anti-aquaporin-4 (AQP4) antibody-positive NMOSD. In March 2023, ENSPRYNG received forerunner designation from Japan's Ministry of Health, Labour, and Welfare (MHLW) for its potential use in treating autoimmune encephalitis. Satralizumab (RG6168) has also been granted orphan drug designation (ODD) by the US FDA for the treatment of autoimmune encephalitis, specifically NMDAR-AE.

Currently, the drug is being assessed in Phase III clinical trials for autoimmune encephalitis, with the first patient enrolled in the third quarter of 2022. Hoffmann-La Roche plans to file a regulatory submission for the treatment of autoimmune encephalitis by 2026.

ART5803: Arialys Therapeutics/Nucleus Network

ART5803, an investigational monoclonal antibody developed by Arialys Therapeutics, is being evaluated for the treatment of anti-NMDAR encephalitis (ANRE). The US FDA has granted ART5803 ODD for autoimmune encephalitis, specifically NMDAR-AIE. In October 2024, Arialys Therapeutics announced the initiation of the Phase I clinical trial, marking a key milestone in advancing precision medicine for autoimmune neuropsychiatric disorders. The trial, conducted in collaboration with Nucleus Network in Melbourne, Australia, will provide safety and pharmacokinetic data from healthy volunteers by mid-2025. Arialys plans to launch a Phase IIa proof-of-concept trial for ART5803 in the second half of 2025, initially targeting patients with anti-NMDAR encephalitis.

Additionally, Arialys Therapeutics aims to submit an IND application to the US FDA by the end of 2024, exploring ART5803 for the potential treatment of autoimmune psychosis. In July 2024, Arialys presented a poster at the American Academy of Neurology (AAN) Summer Conference, titled "Peripherally Administered Therapeutic One-Armed Antibody Reversed Behavioral Abnormalities in a Marmoset Model of Anti-NMDAR Encephalitis."

Drug Class Insights

Currently, there are no approved therapies specifically for autoimmune psychosis, and treatment primarily relies on off-label therapies. The main approach focuses on immune therapies, and tumor removal may be considered if necessary.

Steroids are commonly used to reduce inflammation by suppressing immune system activity, helping control the immune response. Plasma exchange is another key treatment, where harmful antibodies are removed from the blood by drawing blood, separating the plasma, and returning the remaining blood with fresh plasma. This helps mitigate the autoimmune attack. Intravenous immunoglobulins (IVIG), a blood product, are less frequently used but can modulate immune function, block autoantibodies, and restore immune balance.

For patients who do not respond to first-line therapies, rituximab is often recommended. It works by depleting B cells, which produce autoantibodies, and has been shown to reduce the risk of future relapses. In some cases, cyclophosphamide, an immunosuppressive agent, may be used either alone or in combination with rituximab for more effective management of autoimmune psychosis.

Market Outlook

Autoimmune psychosis is a condition marked by isolated psychotic symptoms with few or no neurological signs in patients who test positive for neuronal autoantibodies, particularly those targeting N-methyl-D-aspartate receptors (NMDAR). Although these cases are often considered atypical or mild forms of autoimmune encephalitis, some experts believe their distinct characteristics justify classifying them as a separate condition known as autoimmune psychosis. Diagnosis is based on tests such as MRI, electroencephalogram, blood serology, and lumbar puncture.

Currently, no therapies are specifically approved for autoimmune psychosis, and treatment typically involves off-label immune therapies. These may include immune-suppressing treatments like steroids, plasma exchange, intravenous immunoglobulins, and cyclophosphamide.

The development pipeline for autoimmune psychosis treatment is limited, with satralizumab (RG-6168) and ART5803 being the primary candidates. There is a significant unmet need for targeted treatments, as current therapies focus on symptom management rather than addressing the underlying condition.

• The total market size of autoimmune psychosis in the 7MM was approximately USD 6.07 million in 2023 and is projected to increase during the forecast period (2024-2034).
• The market size for autoimmune psychosis in the US was approximately USD 3.38 million in 2023 and is anticipated to increase due to the launch of emerging therapies.
• The total market size of EU4 and the UK was calculated to be approximately USD 2.03 million in 2023, which was nearly 33% of the total market revenue for the 7MM.
• In 2023, Germany led the market among the EU4 countries and the UK, generating approximately USD 0.62 million, followed by France and the UK, both contributing around USD 0.50 million each.
• In 2023, the total market size of autoimmune psychosis was approximately USD 0.66 million in Japan which is anticipated to increase during the forecast period (2024-2034).
• Estimates suggest that satralizumab is expected to generate approximately USD 27.50 million by 2034 in the 7MM.

Autoimmune Psychosis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034.

Autoimmune Psychosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

Pipeline development activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for autoimmune psychosis.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on autoimmune psychosis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the Johns Hopkins Bloomberg School of Public Health, US, Stanford University School of Medicine, US, University of Freiburg, Germany, Universite de Bordeaux, France, University of Bologna, Italy, University of Oxford, UK, Dokkyo Medical University, Japan, and Ibaraki Prefectural Medical Center of Psychiatry, Japan, among others, were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or autoimmune psychosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician's View

As per the KOLs from the US, autoimmune-related psychosis challenges traditional psychiatric paradigms. In cases like anti-NMDA receptor encephalitis, autoantibodies disrupt synaptic function, leading to severe psychotic features. Early identification through cerebrospinal fluid testing or serum autoantibody panels can change the trajectory of these patients' outcomes, emphasizing the need for immunological workups in psychiatric evaluations

As per the KOLs from France, patients with autoimmune psychosis require individualized care. Immunomodulators like plasmapheresis or rituximab address the root cause, while antipsychotics manage immediate psychiatric symptoms. Striking the right balance can significantly improve long-term outcomes

As per the KOLs from Japan, Japanese psychiatrists have noted that atypical psychoses can resemble antibody-mediated encephalitis, particularly NMDAR encephalitis, with acute onset and symptoms like impaired consciousness, emotional disturbances, and psychomotor abnormalities. Fever, dysautonomia, and a higher prevalence in women are also common. Abnormal EEGs and effective treatments like corticosteroids and ECT suggest a shared autoimmune cause. Early diagnosis and immunotherapy are crucial, especially when psychiatric symptoms precede neurological signs, requiring integrated psychiatric and neurological care.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

To analyze the effectiveness of these therapies, have calculated their attributed analysis by giving them scores based on their ability to improve atrial and ventricular dimension/function and ability to regulate heart rate.

Further, the therapies' safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

DelveInsight's 'Autoimmune Psychosis-Market Insights, Epidemiology, and Market Forecast-2034' report provides a descriptive overview of the market access and reimbursement scenario of autoimmune psychosis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of autoimmune psychosis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the autoimmune psychosis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM autoimmune psychosis market.

Autoimmune psychosis report insights

• Patient Population
• Therapeutic Approaches
• Autoimmune Psychosis Pipeline Analysis
• Autoimmune Psychosis Market Size and Trends
• Existing and Future Market Opportunity

Autoimmune psychosis report key strengths

• 11 years Forecast
• The 7MM Coverage
• Autoimmune Psychosis Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Drugs Uptake and Key Market Forecast Assumptions

Autoimmune psychosis report assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Attribute Analysis)

Key Questions:

Market Insights

• What was the total market size of autoimmune psychosis, the market size of autoimmune psychosis by therapies, and market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
• How will ENSPRYNG (satralizumab, RG6168) affect the treatment paradigm of autoimmune psychosis?
• Which drug is going to be the largest contributor by 2034?
• What are the pricing variations among different geographies for approved and marketed therapies?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of autoimmune psychosis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to autoimmune psychosis?
• What is the historical and forecasted autoimmune psychosis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Out of the countries mentioned above, which country would have the highest diagnosed prevalent autoimmune psychosis population during the forecast period (2024-2034)?
• What factors are contributing to the growth of autoimmune psychosis cases?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of autoimmune psychosis? What are the current clinical and treatment guidelines for treating autoimmune psychosis?
• How many companies are developing therapies for the treatment of autoimmune psychosis?
• How many emerging therapies are in the mid-stage and late stage of development for treating autoimmune psychosis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved therapy in the US?
• What is the 7MM historical and forecasted market of autoimmune psychosis?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the autoimmune psychosis market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying upcoming solid players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies for autoimmune psychosis, barriers to accessibility of approved therapy, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Autoimmune Psychosis by Therapies in the 7MM in 2020
• 3.2. Market Share (%) Distribution of Autoimmune Psychosis by Therapies in the 7MM in 2034

4. Executive Summary

5. Key Events

6. Disease Background and Overview

• 6.1. Introduction
• 6.2. Classification
• 6.3. Causes and Risk Factors
• 6.4. Signs and Symptoms
• 6.5. Diagnosis
  • 6.5.1. Misdiagnosis
  • 6.5.2. Diagnostic Guidelines and Recommendations
  • 6.5.3. Diagnostic Algorithm for Autoimmune Encephalitis
• 6.6. Treatment and Management
  • 6.6.1. Treatment Algorithm for Autoimmune Encephalitis
  • 6.6.2. Treatment Guidelines and Recommendations

7. Methodology

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale
  • 8.2.1. Diagnosed Prevalent Cases of Autoimmune Encephalitis
  • 8.2.2. Total Cases of Autoimmune Encephalitis with Neuronal Surface Antigens
  • 8.2.3. Antibodies-specific Cases of Autoimmune Encephalitis
  • 8.2.4. Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis
  • 8.2.5. Diagnosed Prevalent Cases of Autoimmune Psychosis
  • 8.2.6. Relapsed Cases of Autoimmune Psychosis
• 8.3. Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in the 7MM
• 8.4. Total Diagnosed Prevalent Cases of Autoimmune Psychosis in the 7MM
• 8.5. The US
  • 8.5.1. Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in the US
  • 8.5.2. Total Cases of Autoimmune Encephalitis with Neuronal Surface Antigens in the US
  • 8.5.3. Antibodies-specific Cases of Autoimmune Encephalitis in the US
  • 8.5.4. Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in the US
  • 8.5.5. Total Diagnosed Prevalent Cases of Autoimmune Psychosis in the US
  • 8.5.6. Relapsed Cases of Autoimmune Psychosis in the US
• 8.6. EU4 and the UK
  • 8.6.1. Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in EU4 and the UK
  • 8.6.2. Total Cases of Autoimmune Encephalitis with Neuronal Surface Antigens in EU4 and the UK
  • 8.6.3. Antibodies-specific Cases of Autoimmune Encephalitis in EU4 and the UK
  • 8.6.4. Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in EU4 and the UK
  • 8.6.5. Total Diagnosed Prevalent Cases of Autoimmune Psychosis in EU4 and the UK
  • 8.6.6. Relapsed Cases of Autoimmune Psychosis in EU4 and the UK
• 8.7. Japan
  • 8.7.1. Total Diagnosed Prevalent Cases of Autoimmune Encephalitis in Japan
  • 8.7.2. Total Cases of Autoimmune Encephalitis with Neuronal Surface Antigens in Japan
  • 8.7.3. Antibodies-specific Cases of Autoimmune Encephalitis in Japan
  • 8.7.4. Gender-specific Cases of Anti-NMDAR Autoimmune Encephalitis in Japan
  • 8.7.5. Total Diagnosed Prevalent Cases of Autoimmune Psychosis in Japan
  • 8.7.6. Relapsed Cases of Autoimmune Psychosis in Japan

9. Patient Journey

10. Emerging Drugs

• 10.1. Key Competitors: Emerging Therapies
• 10.2. ENSPRYNG (satralizumab, RG6168): Hoffmann-La Roche (Chugai Pharmaceutical)
  • 10.2.1. Drug Description
  • 10.2.2. Drug Profile
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Clinical Development
  • 10.2.5. Analysts' View
• 10.3. ART5803: Arialys Therapeutics/Nucleus Network
  • 10.3.1. Drug Description
  • 10.3.2. Drug Profile
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Clinical Development
  • 10.3.5. Safety and Efficacy

11. Autoimmune Psychosis - 7MM Market Analysis

• 11.1. Key Findings
• 11.2. Market Outlook
• 11.3. Key Market Forecast Assumptions
  • 11.3.1. Cost Assumptions and Rebates
  • 11.3.2. Pricing Trends
  • 11.3.3. Analogue Assessment
  • 11.3.4. Launch Year and Therapy Uptake
• 11.4. Total Market Size of Autoimmune Psychosis in the 7MM
• 11.5. Market Size of Autoimmune Psychosis by Therapies in the 7MM
• 11.6. The US Market Size
  • 11.6.1. Total Market Size of Autoimmune Psychosis in the US
  • 11.6.2. Market Size of Autoimmune Psychosis by Therapies in the US
• 11.7. EU4 and the UK Market Size
  • 11.7.1. Total Market Size of Autoimmune Psychosis in EU4 and the UK
  • 11.7.2. Market Size of Autoimmune Psychosis by Therapies in EU4 and the UK
• 11.8. Japan Market Size
  • 11.8.1. Total Market Size of Autoimmune Psychosis in Japan
  • 11.8.2. Market Size of Autoimmune Psychosis by Therapies in Japan

12. KOL Views

13. Unmet Needs

14. SWOT

15. Market Access and Reimbursement

• 15.1. The United States
  • 15.1.1. Centre for Medicare & Medicaid Services (CMS)
• 15.2. EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. The United Kingdom
• 15.3. Japan
  • 15.3.1. MHLW

16. Appendix

• 16.1. Acronyms and Abbreviations
• 16.2. Bibliography
• 16.3. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight